What Корнерегель Treats: Main Uses and Benefits

The primary role of Корнерегель is to provide supportive symptomatic management and is relevant for easing symptoms linked to organ-specific functional stress. This medication is commonly used across domains where additional symptomatic support is needed.

This medication is commonly used across conditions where functional stability becomes affected, such as acute corneal abrasions, injuries following eye foreign body removal, postoperative care after procedures like laser surgery, and in cases of severe dry eye syndrome or micro-erosions linked to prolonged contact lens wear. It helps address symptom clusters that may become more disruptive during flare-ups, including sensations of burning, stinging, and foreign body sensation.

Applied in scenarios where additional management of discomfort is required, its use supports the patient during difficult episodes by easing the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods.

“Applied in settings marked by temporary physiological imbalance, this medication provides supportive relief when symptoms interfere with routine activities.”

---

Quick Fact: Relief for Surface Damage The gel plays a role in managing symptoms related to organ-specific functional stress in conditions involving inflammatory or irritative processes, offering symptomatic assistance that helps patients cope more steadily with symptom fluctuations.

Regulatory References

1. National Institutes of Health (NIH) - PubMed Central

Who Can and Cannot Use Корнерегель?

Eligibility for Dexpanthenol ophthalmic gel (Корнерегель) is defined by regulatory authorities primarily based on a single absolute exclusion and specific conditional use guidelines. This information is derived exclusively from official government-approved labeling.

---

Contraindicated Populations

Classification	Population Group
Absolute Contraindication	Patients with a known hypersensitivity to the active substance Dexpanthenol or any excipients.

---

Conditional Use and General Eligibility

Population Group	Regulatory Status
Adults, Children, and Older Adults	Generally Permitted. No specific restrictions or dose adjustments are typically required based on age.
Hepatic/Renal Impairment	Not Restricted. No specific restrictions are documented due to minimal systemic absorption.
Pregnancy and Lactation	Conditional. Use requires the treating doctor to carefully weigh the benefits against possible risks, citing the unknown extent of systemic absorption.
Contact Lens Wearers	Restricted Use. Lenses must be removed before application and may be worn again after approximately 15 minutes.

---

Official regulatory documents define eligibility through this single absolute contraindication, classifying all other typical patient populations as either permitted or requiring caution under specific, documented circumstances.

Interactions with other medicines and products

Official regulatory information for dexpanthenol ophthalmic gel focuses primarily on interactions arising from its formulation as a viscous topical eye preparation.

There are no known systemic drug-drug interactions documented in authoritative regulatory sources, as the active substance, dexpanthenol, is minimally absorbed into the bloodstream following ocular administration. The interaction profile is instead centered on avoiding interference with the efficacy of other locally applied ophthalmic treatments.

Procedural Interaction Constraint

When using Корнерегель in conjunction with other topical eye medicines, a strict procedural constraint must be observed. The viscous nature of the gel can potentially impair the absorption, distribution, or action of other eye preparations if it is applied first.

Interacting Product Category	Constraint/Requirement	Basis of Interaction
Other Topical Ophthalmic Medicines (e.g., eye drops, ointments)	Must be administered last in the sequence of application.	Physical properties of the viscous gel affecting contact/penetration
Time Spacing	A specific time interval should be observed between the application of the ophthalmic gel and other eye medicines.	Ensuring optimal drug exposure for all co-administered products

This constraint is a management strategy to maintain the intended therapeutic effect of all co-administered eye products. Therefore, the gel should always be the final preparation to contact the eye surface.

Molecular Mechanism and Cellular Action

Корнерегель contains dexpanthenol, which functions as a pro-vitamin of pantothenic acid (Vitamin B5). Following absorption into the target ocular epithelial cells, dexpanthenol is rapidly converted via enzymatic activity into pantothenic acid. Pantothenic acid then serves as a mandatory precursor for the intracellular biosynthesis of Coenzyme A (CoA).

CoA is a vital metabolic cofactor required for numerous essential reactions, including the transfer of acyl groups, which is a necessary step in the synthesis of structural components. Specifically, CoA is involved in the formation of lipids and proteins that are fundamental to maintaining cell membrane integrity. This localized enhancement in CoA availability directly modulates the metabolic activity within the tissue, providing the biochemical resources and energy needed for the high rate of cellular proliferation and differentiation inherent in epithelial maintenance.

How to Use Корнерегель: Administration Guidelines

The administration of Dexpanthenol ophthalmic gel follows protocols designed for optimal contact with the eye's surface. The standard administration method is topical instillation directly into the conjunctival sac, with the application being one single drop per dose. This preparation is generally scheduled for a pattern of divided daily dosing, typically applied four times per day. This frequency usually involves three applications during the patient's waking hours and a final application just before sleep, a regimen common in clinical contexts to maximize overnight exposure.

The duration of use is often structured as a finite treatment course, such as a cycle lasting approximately 30 days, though the overall course may be extended depending on the specific need for corneal surface support. No specific, high-level dosage adjustments for special populations, such as older adults, are consistently required or cited in standard product labeling for this topical product.

Procedural constraints are essential for correct use. The gel must not be applied while soft contact lenses are in place; they must be removed prior to application, and reinsertion must be delayed by at least 15 minutes. Furthermore, due to its high-viscosity formulation, the gel is administered last in any sequence involving multiple ophthalmic preparations, requiring a 15-minute interval after all other drops or solutions have been applied.

Research evidence / Overview of Studies for Корнерегель

---

Evidence for Use in Corneal Epithelial Healing

Research examined Dexpanthenol preparations in contexts where corneal re-epithelialization was measured. Studies were evaluated in this context, often utilizing short-term Randomized Controlled Trials (RCTs) and comparative clinical investigations to examine its use in contexts involving corneal epithelial defects following injury, surgery, or abrasion. The primary focus of this research was studied for measuring the time required for epithelial defect closure, a measure tracked using objective staining methods.

The populations evaluated in these clinical trials were often adults who had undergone surface-based laser surgery or had suffered a superficial injury. Research describes measurements of outcomes related to physical discomfort, and studies reported objective measures related to the healing process. However, when compared directly to the inactive gel vehicle, some trials described patterns such as minimal or modest differences in the time needed for the defect to fully close.

Evidence for Use in Dry Eye Syndrome and Ocular Surface Disease

Clinical investigations have explored this preparation for conditions characterized by fluctuating or episodic manifestations of dry eye syndrome. The research includes Randomized Controlled Trials, sometimes designed as non-inferiority trials to see if the preparation was observed in a manner comparable to existing dry eye treatments. These studies were evaluated in adults diagnosed with moderate to severe dry eye, including those reporting outcomes related to physical discomfort after common surgeries.

Researchers examined objective measures like the stability of the tear film and changes in the corneal surface state. Studies described patterns related to changes in measured ocular surface parameters and patient-reported comfort levels.

---

What is Still Uncertain and Research Gaps

Evidence quality varies across studies, with high-level RCTs being more common for corneal healing. Major research gaps include: limited information for long-term outcomes regarding the sustained effects of the preparation on corneal health. The isolated contribution of Dexpanthenol to the outcomes of co-formulated products remains insufficient in many comparative trials, and comparative evidence is lacking for direct head-to-head trials against a wide range of similar high-viscosity ocular gels.

Key Studies & References Clinical data regarding the use of Dexpanthenol for dry eye syndrome and contact lens-related erosions

Common questions about Корнерегель (FAQ)

---

Q: Do I need a prescription to get Корнерегель?

According to the official product information in many jurisdictions, Dexpanthenol 5% eye gel is typically classified as a non-prescription medicine. This means it is often available as an Over-The-Counter (OTC) product or its equivalent, which can generally be obtained without a doctor’s written prescription.

---

Q: What is the difference between Корнерегель and other dexpanthenol eye gels?

Official documents indicate that the core active ingredient, Dexpanthenol, and its concentration are generally the same across these products. Potential differences often relate to the specific inactive ingredients (excipients), such as the gelling agent or the preservative system, which are necessary for the product's formulation.

---

Q: Are there any long-term studies on the use of Корнерегель?

Research overviews often focus on short-term Randomized Controlled Trials to measure objective outcomes like the time required for corneal healing. Official documentation indicates that information regarding sustained effects and long-term outcomes of use is noted as a key research gap.

---

Q: Is Корнерегель used for dry eyes only, or for other surface issues as well?

Official product information describes its purpose as supporting the eye’s natural repair in several contexts. This includes conditions such as corneal epithelial defects following injury or surgery, surface damage due to minor irritations, and conditions characterized by dry eye syndrome.

---

Q: What should I look for on the official product label to confirm its intended purpose?

The label generally specifies the active ingredient as Dexpanthenol and lists its concentration (commonly 5%). The label will also state the preparation’s core purpose, which is to support the epithelial regeneration of the eye’s surface tissues.

---

Q: Are there any ingredients in Корнерегель that are commonly associated with eye irritation?

Regulatory safety documents list local ocular irritation, which can include sensations of burning or stinging, as a documented adverse effect. Due to this potential for irritation, the product is contraindicated in individuals with a known hypersensitivity to the active substance or any excipients.

---

Q: What is the role of the inactive ingredients in the Корнерегель formula?

One key inactive ingredient is the carbomer hydrogel vehicle. Official information highlights that this viscous material helps the preparation to achieve extended contact time on the eye’s surface. This extended contact supports the intended effect of the active ingredient.

---

Q: What should a patient do if they accidentally use more Корнерегель than expected?

Official documents state that because the product is designed for topical use and is only minimally absorbed into the bloodstream, no specific systemic toxicity is expected even in the event of using an amount greater than the recommended dose.

---

Q: Can Корнерегель be used for issues other than those officially listed, such as general eye fatigue?

Official product information describes the drug's purpose as supporting epithelial regeneration for specific injuries, irritations, and dry eye conditions. Use for non-specific issues such as general eye fatigue is not listed among the recognized or documented uses in regulatory documents.

---

Q: Is it necessary to shake the tube or bottle of Корнерегель before use?

The official administration instructions detail the procedure for topical instillation into the conjunctival sac. However, these guidelines do not include any specific instruction to shake the tube or bottle prior to application.

---

Q: What is the official classification of Корнерегель (e.g., medical device, prescription drug, OTC drug) in certain regions?

In numerous major markets, Dexpanthenol 5% ophthalmic gel is regulated as a non-prescription medicine (Over-The-Counter or its equivalent). This means it is classified for non-prescription access and is typically not subject to the same strict controls as a prescription-only drug.

How to Store and Dispose of Corneregel

Official regulatory documentation defines specific requirements for the storage and disposal of Corneregel ophthalmic gel.

Storage Requirements

Condition	Requirement
Maximum Temperature	Store not above 25 C.
Container Integrity	The tube must be kept tightly closed when not in use.
Child Safety	Must be kept out of the sight and reach of children.
Shelf-Life After Opening	Use for no longer than 6 months after first opening the tube.

Disposal Instructions

To protect the environment, the medicine must not be thrown away via wastewater or household waste. Patients are instructed to ask the pharmacist for guidance on how to properly discard unused or expired product.